Under 10% of patients who could benefit from obesity jabs including Wegovy can access them, states the World Health Organization as it releases its inaugural guidance on the medications.
Considering in excess of 1,000,000,000 people worldwide currently living with obesity, it is urging increased and just availability to this class of drugs.
Per estimates, over two billion could be living with obesity by 2030 if no action is taken.
"The new guidance acknowledges that obesity is a long-term condition that can be treated with thorough and lifelong care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are key barriers to widespread availability to the injections that can help people shift considerable body mass, says the agency.
Weight-Loss Drug Shortage
Even under the present best projected case, the supply of these medications would only suffice for about 100 million people – less than 10% of eligible patients, according to the health organization.
The advice encourages governments and firms to expand access, by strategies such as voluntary licensing.
Exclusive production rights on semaglutide – the main component of the drug Wegovy – is scheduled to end in multiple countries in 2026.
The Way Weight-Loss Injections Function
These medications replicate a natural hormone to slow digestion, curb appetite and boost the sense of being full so people consume fewer calories.
Patients commonly start to lose weight within a few weeks of starting on the once-weekly jabs.
Research indicates patients may see weight return after a year of discontinuing the drug, as their normal hunger come back.
To be above a healthy weight increases your risk for contracting medical conditions, such as diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight concerns individuals in every country and was associated with over three and a half million deaths worldwide in 2024, according to the health agency.
